Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

Background:

• Cutaneous leiomyomas are smooth muscle tumors that may arise sporadically or in association with an inherited cancer-related genodermatosis.
• Leiomyomas may be severely painful, and current management is generally unsatisfactory.
• Studies demonstrate increased nerve density within and around leiomyomas as well as increased acetylcholinesterase staining of associated nerves.
• Botulinum toxin-A has been used in the treatment of pain syndromes.
• Based on the known mechanisms of action of botulinum toxin-A, treatment with botulinum toxin-A (BOTOX; Allergan, Inc.), may ameliorate the severe paroxysmal pain of symptomatic cutaneous leiomyomas.

Objectives:

• Primary: To assess change in worst lesional pain in the past week based on Brief Pain Inventory (BPI) from Week 0 to Week 4 in treated patients versus controls.
• Primary: To assess improvement in pain based on Visual Analog Scale (VAS) after application of ice at Week 4 compared to baseline in treated patients versus controls.
• Secondary: To assess change in magnitude and in frequency of painful episodes based on a weekly patient diary in treated patients versus controls.
• Secondary: To assess persistence of pain control at Weeks 12 based on the BPI and VAS.
• Secondary: To assess the frequency of rescue pain medication use in treated patients versus controls during the 24 week study period.
• Secondary: To determine the impact of leiomyoma treatment on quality of life.
• Secondary: To assess change in patient s condition based on the Patient Global Impression of Change.
• Secondary: To evaluate the immunohistochemical staining of nerve fibers and muscle in cutaneous leiomyomas in control and treated lesions following the conclusion of the study.

Eligibility:

• Subjects greater than or equal to18 years with at least 1 symptomatic cutaneous leiomyoma.
• Pain symptoms must occur at least once a week and be characterized as greater than or equal to 5 out of 10.

Design:

• A 12-week double-blind placebo controlled pilot study of 18 subjects with symptomatic leiomyomas will include initial assessment with BPI, photography, and skin biopsies, followed by treatment of subjects who initially received placebo.
• Cutaneous leiomyomas will undergo intralesional injection with botulinum toxin-A.
• Subjects will return at Weeks 4 and 12 for repeat assessment using pain and quality of life questionnaires and photography. Skin biopsies will be performed at week 12.

• INCLUSION CRITERIA:

• Subjects must be age greater than or equal to18 years.
• Subjects must have a prior biopsy-proven diagnosis of cutaneous leiomyoma.
• Subjects must have at least 1 symptomatic leiomyomas or regions less than or equal to 60 cm^2 of leiomyomas with pain characterized as greater than 4 based on a 10-point scale, indicating pain of at least moderate severity.
• Pain episodes must occur at least once a week.
• Subjects must have the ability to participate fully and comply with the procedures of the protocol in the opinion of the investigator.
• Written informed consent has been obtained including consenting to have tissue samples stored, however subjects are allowed to refuse sample storage.
• Negative urine or serum pregnancy test in females of childbearing potential.
• Subjects who are clinically stable such that they can be expected to complete the 24-week study.

Exclusion criteria

• Subjects with allergies to BTX-A.
• Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
• Subjects with neuromuscular junction disorders (ie. myasthenia gravis or Lambert-Eaton syndrome) or peripheral motor neuropathic diseases (ie. amyotrophic lateral sclerosis or motor neuropathy).
• Subjects with infection at the intended sites of injection.
• Subjects who have had prior Botulinum toxin product within the past 6 months.
• Subjects with pain resulting from other disease(s), specifically:

• pain that requires intermittent or ongoing treatment with narcotics
• severe, debilitating, or acute pain originating from sources other than leiomyomas
• Subjects taking pain medications, neuroactive agents, or other therapy directed toward treatment of cutaneous leiomyomas concurrently or within 5 days or 5 half-lives (whichever is longer) of BTX-A treatment, other than specified rescue pain medications). Patients currently on therapy directed toward OTHER mild to moderate chronic pain will be evaluated on a case-by-case basis for inclusion. Patients with well-controlled mild to moderate chronic pain such as that associated with osteoarthritis, who do not require narcotic therapy, will NOT be excluded. Aspirin for pain relief or for other indications is also acceptable.
• Subjects with late-stage cancers or unstable disease (such as hemodynamic instability, i.e., systolic or diastolic blood pressure fall of 20 mm Hg or greater from the stable patient s baseline measurement).
• A condition or situation that, in the investigator's opinion, may put the subject at significant risk or interfere significantly with the subject's participation in the study.